Icl670a


Indications and Reactions:

Role Indications Reactions
Primary
Prophylaxis 21.5%
Iron Overload 18.5%
Myelodysplastic Syndrome 16.2%
Blood Iron Increased 6.3%
Hypertension 6.0%
Aplastic Anaemia 4.2%
Pain 3.2%
Constipation 2.5%
Haemosiderosis 2.5%
Acute Myeloid Leukaemia 2.3%
Aplasia Pure Red Cell 2.3%
Insomnia 2.3%
Sickle Cell Anaemia 2.1%
Type 2 Diabetes Mellitus 1.9%
Hypothyroidism 1.6%
Diabetes Mellitus 1.4%
Headache 1.4%
Thalassaemia Beta 1.4%
Anaemia 1.2%
Neurosis 1.2%
Pyrexia 14.7%
Vomiting 13.7%
Renal Impairment 10.5%
Sepsis 6.3%
Death 5.3%
Thrombocytopenia 5.3%
Upper Respiratory Tract Infection 5.3%
White Blood Cell Count Decreased 5.3%
Urinary Tract Infection 4.2%
Haematocrit Decreased 3.2%
Infection 3.2%
Pneumonia 3.2%
Septic Shock 3.2%
Serum Ferritin Increased 3.2%
White Blood Cell Count Increased 3.2%
Acute Myeloid Leukaemia 2.1%
General Physical Health Deterioration 2.1%
Oedema 2.1%
Otitis Media 2.1%
Premature Baby 2.1%
Secondary
Prophylaxis 27.6%
Iron Overload 16.1%
Myelodysplastic Syndrome 15.9%
Aplasia Pure Red Cell 5.8%
Hypertension 5.6%
Hypothyroidism 4.9%
Aplastic Anaemia 4.7%
Type 2 Diabetes Mellitus 2.9%
Neurosis 2.5%
Skin Ulcer 2.5%
Osteoporosis 1.9%
Blood Iron Increased 1.5%
Thalassaemia Beta 1.5%
Hepatic Function Abnormal 1.4%
Headache 1.0%
Porphyria Non-acute 1.0%
Constipation 0.8%
Haemosiderosis 0.8%
Cardiac Failure 0.7%
Cardiac Failure Chronic 0.7%
Renal Impairment 13.0%
Vomiting 8.3%
Thrombocytopenia 7.4%
White Blood Cell Count Decreased 7.4%
Foot Fracture 6.5%
Visual Field Defect 6.5%
Sepsis 5.6%
Pancreatitis Acute 4.6%
Sinusitis 4.6%
Subcutaneous Abscess 4.6%
Pneumonia 3.7%
Rash 3.7%
Therapeutic Response Decreased 3.7%
Vertigo 3.7%
Asthenia 2.8%
Creatinine Renal Clearance Decreased 2.8%
Disease Progression 2.8%
Haemolytic Anaemia 2.8%
Infection 2.8%
Renal Tubular Disorder 2.8%

Drug Data